DNA methylation in glioblastoma: impact on gene expression and clinical outcome. - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue BMC Genomics Année : 2010

DNA methylation in glioblastoma: impact on gene expression and clinical outcome.

Marc Aubry
Philippe Menei
  • Fonction : Auteur
  • PersonId : 910996
  • IdRef : 076585468

Résumé

BACKGROUND: Changes in promoter DNA methylation pattern of genes involved in key biological pathways have been reported in glioblastoma. Genome-wide assessments of DNA methylation levels are now required to decipher the epigenetic events involved in the aggressive phenotype of glioblastoma, and to guide new treatment strategies. RESULTS: We performed a whole-genome integrative analysis of methylation and gene expression profiles in 40 newly diagnosed glioblastoma patients. We also screened for associations between the level of methylation of CpG sites and overall survival in a cohort of 50 patients uniformly treated by surgery, radiotherapy and chemotherapy with concomitant and adjuvant temozolomide (STUPP protocol). The methylation analysis identified 616 CpG sites differentially methylated between glioblastoma and control brain, a quarter of which was differentially expressed in a concordant way. Thirteen of the genes with concordant CpG sites displayed an inverse correlation between promoter methylation and expression level in glioblastomas: B3GNT5, FABP7, ZNF217, BST2, OAS1, SLC13A5, GSTM5, ME1, UBXD3, TSPYL5, FAAH, C7orf13, and C3orf14. Survival analysis identified six CpG sites associated with overall survival. SOX10 promoter methylation status (two CpG sites) stratified patients similarly to MGMT status, but with a higher Area Under the Curve (0.78 vs. 0.71, p-value < 5e-04). The methylation status of the FNDC3B, TBX3, DGKI, and FSD1 promoters identified patients with MGMT-methylated tumors that did not respond to STUPP treatment (p-value < 1e-04). CONCLUSIONS: This study provides the first genome-wide integrative analysis of DNA methylation and gene expression profiles obtained from the same GBM cohort. We also present a methylome-based survival analysis for one of the largest uniformly treated GBM cohort ever studied, for more than 27,000 CpG sites. We have identified genes whose expression may be tightly regulated by epigenetic mechanisms and markers that may guide treatment decisions.
Fichier principal
Vignette du fichier
1471-2164-11-701.pdf (892.63 Ko) Télécharger le fichier
1471-2164-11-701-S1.TIFF (38.6 Ko) Télécharger le fichier
1471-2164-11-701-S10.TIFF (155.51 Ko) Télécharger le fichier
1471-2164-11-701-S2.XLS (566.5 Ko) Télécharger le fichier
1471-2164-11-701-S3.XLS (155.5 Ko) Télécharger le fichier
1471-2164-11-701-S4.XLS (117 Ko) Télécharger le fichier
1471-2164-11-701-S5.XLS (119.5 Ko) Télécharger le fichier
1471-2164-11-701-S6.XLS (58 Ko) Télécharger le fichier
1471-2164-11-701-S7.TIFF (153.46 Ko) Télécharger le fichier
1471-2164-11-701-S8.TIFF (160.65 Ko) Télécharger le fichier
1471-2164-11-701-S9.XLS (18 Ko) Télécharger le fichier
1471-2164-11-701.xml (80.56 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Format : Autre
Format : Autre
Format : Autre
Format : Autre
Format : Autre
Format : Autre
Format : Autre
Format : Autre
Format : Autre
Format : Autre
Format : Autre
Loading...

Dates et versions

inserm-00663706 , version 1 (27-01-2012)

Identifiants

Citer

Amandine Etcheverry, Marc Aubry, Marie de Tayrac, Elodie Vauleon, Rachel Boniface, et al.. DNA methylation in glioblastoma: impact on gene expression and clinical outcome.. BMC Genomics, 2010, 11 (1), pp.701. ⟨10.1186/1471-2164-11-701⟩. ⟨inserm-00663706⟩
322 Consultations
306 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More